AstraZeneca and the Medicines for Malaria Venture have announced a collaboration to identify novel candidate drugs for the treatment of malaria.

SV Life Sciences has announced the final closing of its newest fund, SV Life Sciences Fund V, at over $523 million, well exceeding its target of $400 million.

An international public-private consortium, set up to build the most detailed map of human genetic variation to date, has announced the completion of three pilot projects.